Skip to main content

Reviews from Journal of Experimental & Clinical Cancer Research

Below is a summary of all reviews published in JECCR

Page 1 of 6

  1. The immune checkpoint molecule CD70 and its receptor CD27 are aberrantly expressed in many hematological and solid malignancies. Dysregulation of the CD70-CD27 axis within the tumor and its microenvironment is...

    Authors: Tal Flieswasser, Astrid Van den Eynde, Jonas Van Audenaerde, Jorrit De Waele, Filip Lardon, Carsten Riether, Hans de Haard, Evelien Smits, Patrick Pauwels and Julie Jacobs
    Citation: Journal of Experimental & Clinical Cancer Research 2022 41:12
  2. micro(mi)RNAs are short noncoding RNAs that through their seed sequence (pos. 2–7/8 of the guide strand) regulate cell function by targeting complementary sequences (seed matches) located mostly in the 3′ untr...

    Authors: Ashley Haluck-Kangas, Monal Patel, Bidur Paudel, Aparajitha Vaidyanathan, Andrea E. Murmann and Marcus E. Peter
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:389
  3. Short or small interfering RNAs (siRNAs) and microRNA (miRNAs) are molecules similar in size and function able to inhibit gene expression based on their complementarity with mRNA sequences, inducing the degrad...

    Authors: Rossana Cuciniello, Stefania Filosa and Stefania Crispi
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:383

    The Correction to this article has been published in Journal of Experimental & Clinical Cancer Research 2021 40:403

  4. Despite  improvements in outcome, 15-25% of newly diagnosed multiple myeloma (MM) patients have treatment resistant high-risk (HR) disease with a poor survival. The lack of a genetic basis for HR has focused a...

    Authors: Hussein Ghamlouch, Eileen M. Boyle, Patrick Blaney, Yubao Wang, Jinyoung Choi, Louis Williams, Michael Bauer, Daniel Auclair, Benedetto Bruno, Brian A. Walker, Faith E. Davies and Gareth J. Morgan
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:380
  5. Nonsense-mediated mRNA decay (NMD) is a highly conserved cellular surveillance mechanism, commonly studied for its role in mRNA quality control because of its capacity of degrading mutated mRNAs that would pro...

    Authors: Roberta Bongiorno, Mario Paolo Colombo and Daniele Lecis
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:376
  6. Breast cancer is one of the most-common female malignancies with a high risk of relapse and distant metastasis. The distant metastasis of breast cancer exhibits organotropism, including brain, lung, liver and ...

    Authors: Cenzhu Wang, Kun Xu, Runtian Wang, Xin Han, Jinhai Tang and Xiaoxiang Guan
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:370
  7. Chimeric antigen receptor (CAR) T-cell therapy has yielded impressive outcomes and transformed treatment algorithms for hematological malignancies. To date, five CAR T-cell products have been approved by the U...

    Authors: Xinyi Xiao, Shengkang Huang, Sifei Chen, Yazhuo Wang, Qihang Sun, Xinjie Xu and Yuhua Li
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:367
  8. Protein ubiquitination is one of the most crucial posttranslational modifications responsible for regulating the stability and activity of proteins involved in homeostatic cellular function. Inconsistencies in...

    Authors: Ravi Chauhan, Ajaz A. Bhat, Tariq Masoodi, Puneet Bagga, Ravinder Reddy, Ashna Gupta, Zahoor Ahmad Sheikh, Muzafar A. Macha, Mohammad Haris and Mayank Singh
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:356
  9. The hopeful outcomes from 30 years of research in BH3-mimetics have indeed served a number of solid paradigms for targeting intermediates from the apoptosis pathway in a variety of diseased states. Not only ha...

    Authors: Paul A. Townsend, Maria V. Kozhevnikova, Olivier N. F. Cexus, Andrey A. Zamyatnin Jr and Surinder M. Soond
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:355
  10. Disordered chromatin remodeling regulation has emerged as an essential driving factor for cancers. Imitation switch (ISWI) family are evolutionarily conserved ATP-dependent chromatin remodeling complexes, whic...

    Authors: Yanan Li, Han Gong, Pan Wang, Yu Zhu, Hongling Peng, Yajuan Cui, Heng Li, Jing Liu and Zi Wang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:346
  11. Fibroblast growth factors (FGFs) and their receptors (FGFRs) play critical roles in many biological processes and developmental functions. Chromosomal translocation of FGFRs result in the formation of chimeric...

    Authors: Lingfeng Chen, Yanmei Zhang, Lina Yin, Binhao Cai, Ping Huang, Xiaokun Li and Guang Liang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:345
  12. Mounting evidence indicates that vitamin C has the potential to be a potent anti-cancer agent when administered intravenously and in high doses (high-dose IVC). Early phase clinical trials have confirmed safet...

    Authors: Franziska Böttger, Andrea Vallés-Martí, Loraine Cahn and Connie R. Jimenez
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:343
  13. Epithelial ovarian cancer (EOC) harbors distinct genetic features such as homologous recombination repair (HRR) deficiency, and therefore may respond to poly ADP-ribose polymerase inhibitors (PARPi). Over the ...

    Authors: Mengyu Tao and Xia Wu
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:338
  14. Oxaliplatin (OHP)-induced peripheral neurotoxicity (OIPN) is a severe clinical problem and potentially permanent side effect of cancer treatment. For the management of OIPN, accurate diagnosis and understandin...

    Authors: Yang Yang, Bing Zhao, Xuejiao Gao, Jinbing Sun, Juan Ye, Jun Li and Peng Cao
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:331
  15. Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8...

    Authors: Jing Zhou, Qing Ji and Qi Li
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:328
  16. The efficacy of cancer immunotherapy largely depends on the tumor microenvironment, especially the tumor immune microenvironment. Emerging studies have claimed that microbes reside within tumor cells and immun...

    Authors: Jiayao Ma, Lingjuan Huang, Die Hu, Shan Zeng, Ying Han and Hong Shen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:327
  17. Despite the overall clinical success of immune checkpoint inhibitors (ICIs) for treating patients with solid tumors, a large number of patients do not benefit from this approach. Consequently, there is a need ...

    Authors: Christina Jensen, Neel I. Nissen, Claus S. Von Arenstorff, Morten A. Karsdal and Nicholas Willumsen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:326
  18. Chronic Lymphocytic Leukemia (CLL) is a hematological malignancy characterized by uncontrolled proliferation of B-cells and severe immune dysfunction. Chemo(immuno)therapies (CIT) have traditionally aimed to r...

    Authors: Carol Moreno, Cecilia Muñoz, María José Terol, José-Ángel Hernández-Rivas and Miguel Villanueva
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:321
  19. The success of antibodies targeting Programmed cell death protein 1 (PD-1) and its ligand L1 (PD-L1) in cancer treatment and the need for improving response rates has led to an increased demand for the develop...

    Authors: Vincent Lemaire, Colby S. Shemesh and Anand Rotte
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:311
  20. Kidney cancer is a common urological tumour. Owing to its high prevalence and mortality rate, it is the third most malignant tumour of the urinary system, followed by prostate and bladder cancers. It exerts a ...

    Authors: Weipu Mao, Keyi Wang, Zonglin Wu, Bin Xu and Ming Chen
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:305
  21. The recent discovery of immune checkpoint inhibitors is a significant milestone in cancer immunotherapy research. However, some patients with primary or adaptive drug resistance might not benefit from the over...

    Authors: Taofei Zeng, Yuqing Cao, Tianqiang Jin, Yu Tian, Chaoliu Dai and Feng Xu
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:285
  22. Epithelial ovarian cancer (EOC) is the most common gynecologic disorder. Even with the recent progresses made towards the use of new therapeutics, it still represents the most lethal gynecologic malignancy in ...

    Authors: Delphine Fessart, Jacques Robert, Cecile Hartog, Eric Chevet, Frederic Delom and Guillaume Babin
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:271
  23. Cancer immunotherapy has gained attention as the supreme therapeutic modality for the treatment of various malignancies. Adoptive T-cell therapy (ACT) is one of the most distinctive modalities of this therapeu...

    Authors: Sasan Ghaffari, Nastaran Khalili and Nima Rezaei
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:269
  24. Immune checkpoint molecules, also known as cosignaling molecules, are pivotal cell-surface molecules that control immune cell responses by either promoting (costimulatory molecules) or inhibiting (coinhibitory...

    Authors: Baokang Wu, Chongli Zhong, Qi Lang, Zhiyun Liang, Yizhou Zhang, Xin Zhao, Yang Yu, Heming Zhang, Feng Xu and Yu Tian
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:267
  25. Autophagy is an intracellular degradation system that removes unnecessary or dysfunctional components and recycles them for other cellular functions. Over the years, a mutual regulation between lipid metabolis...

    Authors: Francesca Ascenzi, Claudia De Vitis, Marcello Maugeri-Saccà, Christian Napoli, Gennaro Ciliberto and Rita Mancini
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:265
  26. Tumor resistance to apoptosis and the immunosuppressive tumor microenvironment are two major contributors to poor therapeutic responses during cancer intervention. Pyroptosis, a lytic and inflammatory programm...

    Authors: Reid Loveless, Ryan Bloomquist and Yong Teng
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:264
  27. Mutant isocitrate dehydrogenase 1/2 (mIDH1/2) gain a novel function for the conversion of α-ketoglutarate (α-KG) to oncometabolite R-2-hydroxyglutarate (R-2-HG). Two molecular entities namely enasidenib (AG-221) ...

    Authors: Kun Yao, Hua Liu, Jiajun Yin, Jianmin Yuan and Hong Tao
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:263
  28. The incidence of renal cell carcinoma (RCC) is increasing worldwide with an approximate 20% mortality rate. The challenge in RCC is the therapy-resistance. Cancer resistance to treatment employs multiple mecha...

    Authors: Fengzhi Li, Ieman A. M. Aljahdali, Renyuan Zhang, Kent L. Nastiuk, John J. Krolewski and Xiang Ling
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:254
  29. Primary liver cancer (PLC) is a common malignancy with high morbidity and mortality. Poor prognosis and easy recurrence on PLC patients calls for optimizations of the current conventional treatments and the ex...

    Authors: Yuanyuan Zheng, Yan Li, Jiao Feng, Jingjing Li, Jie Ji, Liwei Wu, Qiang Yu, Weiqi Dai, Jianye Wu, Yingqun Zhou and Chuanyong Guo
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:250
  30. Cellular senescence is a complex physiological state whose main feature is proliferative arrest. Cellular senescence can be considered the reverse of cell immortalization and continuous tumor growth. However, ...

    Authors: Daniel Otero-Albiol and Amancio Carnero
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:243
  31. Immunotherapeutic treatments are gaining attention due to their effective anti-tumor response. Particularly, the revolution of immune checkpoint inhibitors (ICIs) produces promising outcomes for various cancer...

    Authors: Krishnapriya M. Varier, Hemavathi Dhandapani, Wuling Liu, Jialei Song, Chunlin Wang, Anling Hu, Yaacov Ben-David, Xiangchun Shen, Yanmei Li and Babu Gajendran
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:242
  32. As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effec...

    Authors: Wen Jiang, Jin-Wei Hu, Xu-Ran He, Wei-Lin Jin and Xin-Yang He
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:241
  33. The yearly Think Tank Meeting of the Italian Network for Tumor Biotherapy (NIBIT) Foundation, brings together in Siena, Tuscany (Italy), experts in immuno-oncology to review the learnings from current immunoth...

    Authors: Michele Maio, Michael Lahn, Anna Maria Di Giacomo, Alessia Covre, Luana Calabrò, Ramy Ibrahim and Bernard Fox
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:240
  34. Extracellular vesicles (EVs) containing specific subsets of functional biomolecules are released by all cell types and analysis of circulating EVs can provide diagnostic and prognostic information. To date, li...

    Authors: Francesca Pontis, Luca Roz, Mavis Mensah, Miriam Segale, Massimo Moro, Giulia Bertolini, Ilaria Petraroia, Giovanni Centonze, Anna Maria Ferretti, Paola Suatoni, Ugo Pastorino, Orazio Fortunato and Gabriella Sozzi
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:237
  35. Neutrophils are the most abundant type of white blood cells circulating throughout the bloodstream and are often considered the frontline defenders in innate immunity. However, neutrophils are increasingly bei...

    Authors: Livia Ronchetti, Nouha Setti Boubaker, Maddalena Barba, Patrizia Vici, Aymone Gurtner and Giulia Piaggio
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:231
  36. Tumor immunity consists of various types of cells, which serve an important role in antitumor therapy. The gastrointestinal tract is colonized by trillions of microorganisms, which form the gut microbiota. In ...

    Authors: Xinyi Liu, Yanjie Chen, Si Zhang and Ling Dong
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:221
  37. It has been well documented that the tumor microenvironment (TME) plays a key role in the promotion of drug resistance, the support of tumor progression, invasiveness, metastasis, and even the maintenance of a...

    Authors: Pablo Hernández-Camarero, Elena López-Ruiz, Juan Antonio Marchal and Macarena Perán
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:217
  38. Immunotherapy is currently under intensive investigation as a potential breakthrough treatment option for glioblastoma. Given the anatomical and immunological complexities surrounding glioblastoma, lymphocytes...

    Authors: Jorrit De Waele, Tias Verhezen, Sanne van der Heijden, Zwi N. Berneman, Marc Peeters, Filip Lardon, An Wouters and Evelien L. J. M. Smits
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:213
  39. Defects in the DNA damage response (DDR) can lead to genome instability, producing mutations or aberrations that promote the development and progression of cancer. But it also confers such cells vulnerable to ...

    Authors: Yali Wang, Kun Zheng, Yongbiao Huang, Hua Xiong, Jinfang Su, Rui Chen and Yanmei Zou
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:211
  40. Nasopharyngeal carcinoma (NPC) represents a molecularly paradigmatic tumor given the complex diversity of environmental as well as host dependent factors that are closely implicated in tissue transformation an...

    Authors: Ramon Yarza, Mateo Bover, Maria Teresa Agulló-Ortuño and Lara Carmen Iglesias-Docampo
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:202
  41. Hypoxia in solid tumors is an important predictor of treatment resistance and poor clinical outcome. The significance of hypoxia in the development of resistance to radiotherapy has been recognized for decades...

    Authors: Irma Telarovic, Roland H. Wenger and Martin Pruschy
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:197
  42. Bcl-x pre-mRNA splicing serves as a typical example to study the impact of alternative splicing in the modulation of cell death. Dysregulation of Bcl-x apoptotic isoforms caused by precarious equilibrium splic...

    Authors: Zhihui Dou, Dapeng Zhao, Xiaohua Chen, Caipeng Xu, Xiaodong Jin, Xuetian Zhang, Yupei Wang, Xiaodong Xie, Qiang Li, Cuixia Di and Hong Zhang
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:194
  43. Neuroblastoma is the most common extra-cranial solid tumor in children, representing approximately 8% of all malignant childhood tumors and 15% of pediatric cancer-related deaths. Recent sequencing and transcr...

    Authors: Vid Mlakar, Edouard Morel, Simona Jurkovic Mlakar, Marc Ansari and Fabienne Gumy-Pause
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:189
  44. Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have been the mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its early promising results in decre...

    Authors: Revati Sharma, Elif Kadife, Mark Myers, George Kannourakis, Prashanth Prithviraj and Nuzhat Ahmed
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:186
  45. Colorectal cancer (CRC) is a complex and heterogeneous disease, characterized by dismal prognosis and low survival rate in the advanced (metastatic) stage. During the last decade, the establishment of novel pr...

    Authors: Erika Durinikova, Kristi Buzo and Sabrina Arena
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:185
  46. The cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4)/B7 and programmed death 1 (PD-1)/ programmed cell death-ligand 1 (PD-L1) are two most representative immune checkpoint pathways, which negatively regula...

    Authors: Hao Zhang, Ziyu Dai, Wantao Wu, Zeyu Wang, Nan Zhang, Liyang Zhang, Wen-Jing Zeng, Zhixiong Liu and Quan Cheng
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:184
  47. Colorectal cancer (CRC), despite the advances in screening and surveillance, remains the second most common cause of cancer death worldwide. The biological inadequacy of pre-clinical models to fully recapitula...

    Authors: Giulia Rizzo, Andrea Bertotti, Simonetta Maria Leto and Stefania Vetrano
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:178
  48. Although new developments of surgery, chemotherapy, radiotherapy, and immunotherapy treatments for cancer have improved patient survival, the emergence of chemoresistance in cancer has significant impacts on t...

    Authors: Guo-Hua Li, Qiang Qu, Ting-Ting Qi, Xin-Qi Teng, Hai-Hong Zhu, Jiao-Jiao Wang, Qiong Lu and Jian Qu
    Citation: Journal of Experimental & Clinical Cancer Research 2021 40:174